Austin, Texas – April 20, 2016 – Lumos Pharma, Inc. a clinical stage biotechnology company focused on bringing novel therapies to patients with unmet medical needs in severe, rare, and genetic diseases, announced that John C. McKew, Ph.D. has joined the company as its Chief Scientific Officer. “John is one of the most well-known and […]

READ MORE

Austin, Texas – April 13, 2016 –  Lumos Pharma, Inc., a biotechnology company focused on bringing novel therapies to patients with unmet medical needs in severe, rare, and genetic diseases, announced that David M. Weiner, M.D. has joined the company as its Chief Medical Officer. “Dave’s accomplishments in the pharmaceutical industry and extensive clinical experience […]

READ MORE

AUSTIN, Texas – April 6, 2016 – Lumos Pharma, a biotechnology company focused on developing therapeutics for orphan diseases, announced the successful completion of a $34 million Series B financing.  Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will […]

READ MORE

AUSTIN, Texas – February 16, 2016 – In recognition of Rare Disease Day, members of the Lumos team will attending the local Rare Disease Day event, Cup of Hope, a chili cook-off, sponsored by U.R. Our Hope, in Kyle, Texas on Saturday, February 20th.   Also in attendance and hosting a booth, will be Whitnie Strauss, Vice […]

READ MORE

AUSTIN, Texas – February 4th, 2014 – Lumos Pharma, an early stage biopharmaceutical development company, announced today that it has raised $14 million in Series A financing. The round was co-led by Santé Ventures and New Enterprise Associates (NEA). Lumos Pharma will use the financing to support the preclinical and clinical development of its lead […]

READ MORE